Popular on TelAve
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- TCAA Welcomes Adolfo Gomez Sanchez to Its Family of Talented Speakers
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
Global Diabetes Drug Market will be US$ 78.10 Billion by 2026 | Renub Research
TelAve News/10634174
According to the latest report by Renub Research, titled "Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company" Diabetes drugs are used to treat pre-diabetes and diabetes mellitus type 2 by controlling the blood glucose level of the body. There are different classes of medicine for the treatment of this diabetes, which are given to patients through oral, intravenous, and subcutaneous routes. According to Renub Research analysis, Global Diabetes Drug Market is forecasted to be US$ 78.10 Billion by 2026. This growth is due to the rising number of diabetes patients worldwide, increasing per capita income. Another reason is with the use of machines; people are following a sedentary lifestyle, which leads to obesity, a decline of physical activity, and consumption of unhealthy meals. Besides, growth in the ageing population is also one of the other reason.
According to WHO stats, the number of diabetes patients has risen to 422 Million in the year 2014 from 108 Million in the year 1980. The prevalence of diabetes patients for adults ageing more than 18 years was 4.7 percent in the year 1980, which has risen to 8.5 percent in the year 2014. Initially, diabetes was limited to only a small region of the world; now, it has been growing in middle and low-income countries at a faster pace. This disease leads to several life-threatening diseases such as heart attacks, stroke, kidney failure, blindness, and lower limb amputation. This disease was the reason for 1.6 Million deaths in the year 2016. Diabetes was the 7th leading reason for death in the year 2016.
To avoid this disease, WHO has given prevention through which an individual can live a healthy life, such as to prevent or delay type 2 diabetes people should have and manage a healthy BMI (Body Mass Index) ratio. Physical exercise of at least 30 minutes of regular and moderate-intensity activity should be done daily for weight control. Diet should be healthy without saturated fat and sugar. The use of tobacco should be avoided, as smoking is liable for the risk of diabetes, heart ailments, and respiratory disorders.
More on TelAve News
COVID-19 impact on Diabetes Drug Market
Most of the countries are affected by COVID-19 pandemic, the healthcare system and economic activities are disturbed by lockdown imposed by governments. Currently, treatment of COVID-19 is the priority of healthcare department, and hospitals have stopped treatment of other diseases as beds are reserved for COVID-19 patients. Diabetes patients have to depend on medicines prescribed by doctors, and governments are investing heavily in their healthcare systems. This will also help in research and development of diabetes drugs which is propelled by massive investment in the pharma industry.
The global diabetes drug market will grow in the future due to the increasing adoption of diabetes drugs in the following nations such as the United Kingdom, China, Germany, India, France, Japan, and Spain.
Most of the small and big market players are launching new diabetes drugs at regular intervals; besides, this collaboration, partnership, expansion, and acquisition between them will also propel the global diabetes drugs market.
There are numerous diabetes drugs used to treat type 2 diabetes, such as Lantus subcutaneous, Metformin, Avandia, Invokana, and Actos. All drugs are given orally expect insulin, Pramlintide, Exenatide, and Liraglutide. Insulin is injected through delivery devices, including insulin syringe, intravenous sets, jet injectors, infusion pump, and insulin pen.
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php...
Market Summary:
By Disease: This research report has covered the market of Type 1, Type 2 diabetes, according to Renub Research analysis.
Oral Therapy: The market for following Oral Therapies is covered in this report, such as Biguanide, SGLT-2, Alpha Glucosidase Inhibitor, (DPP) IV Inhibitor, and Others Oral Drug.
More on TelAve News
By Injection: This report gives the market for following injection Glucagon-like peptide (GLP) 1 agonist, Amylin receptor against
By Insulin: The market for following insulin types are covered in the research report: Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin, and Other Insulin.
By Regions: The following regions are covered in the research report Japan, India, United States, 5European Union, Canada, China, and Brazil.
By Company: Overview, R&D Pipeline and Sales Analysis of Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson are given in the research report.
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research
According to WHO stats, the number of diabetes patients has risen to 422 Million in the year 2014 from 108 Million in the year 1980. The prevalence of diabetes patients for adults ageing more than 18 years was 4.7 percent in the year 1980, which has risen to 8.5 percent in the year 2014. Initially, diabetes was limited to only a small region of the world; now, it has been growing in middle and low-income countries at a faster pace. This disease leads to several life-threatening diseases such as heart attacks, stroke, kidney failure, blindness, and lower limb amputation. This disease was the reason for 1.6 Million deaths in the year 2016. Diabetes was the 7th leading reason for death in the year 2016.
To avoid this disease, WHO has given prevention through which an individual can live a healthy life, such as to prevent or delay type 2 diabetes people should have and manage a healthy BMI (Body Mass Index) ratio. Physical exercise of at least 30 minutes of regular and moderate-intensity activity should be done daily for weight control. Diet should be healthy without saturated fat and sugar. The use of tobacco should be avoided, as smoking is liable for the risk of diabetes, heart ailments, and respiratory disorders.
More on TelAve News
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
COVID-19 impact on Diabetes Drug Market
Most of the countries are affected by COVID-19 pandemic, the healthcare system and economic activities are disturbed by lockdown imposed by governments. Currently, treatment of COVID-19 is the priority of healthcare department, and hospitals have stopped treatment of other diseases as beds are reserved for COVID-19 patients. Diabetes patients have to depend on medicines prescribed by doctors, and governments are investing heavily in their healthcare systems. This will also help in research and development of diabetes drugs which is propelled by massive investment in the pharma industry.
The global diabetes drug market will grow in the future due to the increasing adoption of diabetes drugs in the following nations such as the United Kingdom, China, Germany, India, France, Japan, and Spain.
Most of the small and big market players are launching new diabetes drugs at regular intervals; besides, this collaboration, partnership, expansion, and acquisition between them will also propel the global diabetes drugs market.
There are numerous diabetes drugs used to treat type 2 diabetes, such as Lantus subcutaneous, Metformin, Avandia, Invokana, and Actos. All drugs are given orally expect insulin, Pramlintide, Exenatide, and Liraglutide. Insulin is injected through delivery devices, including insulin syringe, intravenous sets, jet injectors, infusion pump, and insulin pen.
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php...
Market Summary:
By Disease: This research report has covered the market of Type 1, Type 2 diabetes, according to Renub Research analysis.
Oral Therapy: The market for following Oral Therapies is covered in this report, such as Biguanide, SGLT-2, Alpha Glucosidase Inhibitor, (DPP) IV Inhibitor, and Others Oral Drug.
More on TelAve News
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Nonprofit innovator named Mensa Executive Director
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- Chasing Elizabeth Taylor — The Dazzling True Story Behind the Queen of Diamonds Now Available in Limited-Edition Hardcover
By Injection: This report gives the market for following injection Glucagon-like peptide (GLP) 1 agonist, Amylin receptor against
By Insulin: The market for following insulin types are covered in the research report: Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin, and Other Insulin.
By Regions: The following regions are covered in the research report Japan, India, United States, 5European Union, Canada, China, and Brazil.
By Company: Overview, R&D Pipeline and Sales Analysis of Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson are given in the research report.
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research
0 Comments
Latest on TelAve News
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Cellhire boosts its EE offering via deal with BT Wholesale's Complete Mobile
- 24/7 customizable AI answering service from Kell Web Solutions, Inc. helps businesses never miss a customer call, lead, or appointment again
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety